Literature DB >> 15761656

Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.

Mirta Knoepfelmacher1, Miriam C Gomes, Maria E Melo, Berenice B Mendonca.   

Abstract

Pituitary adenomas are rare in young patients. Prolactinomas are the most common type of pituitary adenomas in children older than 12 years, occurring more often in girls, at a 4.5:1 female-to-male ratio. The clinical presentation may vary according to the age and sex of the patient. Pituitary apoplexy is a rare life-threatening condition caused by a sudden infarction or hemorrhagic necrosis of the pituitary containing an adenoma. A wide variety of conditions can trigger apoplexy such as pituitary irradiation, general anesthesia, traumatic head injury, pituitary stimulatory tests and a wide variety of medications including bromocriptine. We report a case of a 16-year-old male patient with puberty arrest harboring a macroprolactinoma, who developed a sudden clinical picture of pituitary apoplexy during the 12th month of treatment with cabergoline.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15761656     DOI: 10.1007/s11102-005-5349-x

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  26 in total

1.  Treatment of macroprolactinoma with cabergoline: a study of 85 patients.

Authors:  C I Ferrari; R Abs; J S Bevan; G Brabant; E Ciccarelli; T Motta; M Mucci; M Muratori; L Musatti; G Verbessem; M F Scanlon
Journal:  Clin Endocrinol (Oxf)       Date:  1997-04       Impact factor: 3.478

2.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

3.  Hemorrhage, necrosis, and apoplexy in pituitary adenomas.

Authors:  G Mohr; J Hardy
Journal:  Surg Neurol       Date:  1982-09

4.  Precipitating factors in pituitary apoplexy.

Authors:  V Biousse; N J Newman; N M Oyesiku
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

5.  Pituitary apoplexy: its incidence and clinical significance.

Authors:  S Wakai; T Fukushima; A Teramoto; K Sano
Journal:  J Neurosurg       Date:  1981-08       Impact factor: 5.115

Review 6.  Pituitary apoplexy.

Authors:  C A Rolih; K P Ober
Journal:  Endocrinol Metab Clin North Am       Date:  1993-06       Impact factor: 4.741

7.  Excessively high prolactin level in a patient with a nonprolactin-secreting adenoma. Case report.

Authors:  F C Albuquerque; D R Hinton; M H Weiss
Journal:  J Neurosurg       Date:  1998-12       Impact factor: 5.115

8.  Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.

Authors:  A Colao; A Di Sarno; M L Landi; S Cirillo; F Sarnacchiaro; G Facciolli; R Pivonello; M Cataldi; B Merola; L Annunziato; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

9.  Pituitary apoplexy in an adolescent with prolactin-secreting adenoma.

Authors:  G Pinto; M Zerah; C Trivin; R Brauner
Journal:  Horm Res       Date:  1998

10.  [Pituitary apoplexy followed by endocrine remission. Report of two cases].

Authors:  M Miranda; L Barros; M Knopfelmacher; E C Augusto; A Jacomossi; A Cukiert; L R Salgado; M Nery; J Goldman; B Liberman
Journal:  Arq Neuropsiquiatr       Date:  1998-09       Impact factor: 1.420

View more
  16 in total

1.  Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma.

Authors:  M Alberiche Ruano; M Boronat Cortés; A Ojeda Pino; C Rodriguez Perez; M Gracía Nuñez; D Marrero Arencibia; F J Novoa Mogollón
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 3.  Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review.

Authors:  Tomáš Česák; Pavel Poczos; Jaroslav Adamkov; Jiří Náhlovský; Petra Kašparová; Filip Gabalec; Petr Čelakovský; Ondrej Choutka
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

Review 4.  Pituitary tumors in children: clinical analysis of 21 cases.

Authors:  M Mehrazin
Journal:  Childs Nerv Syst       Date:  2006-12-02       Impact factor: 1.475

5.  Pediatric ischemic stroke from an apoplectic prolactinoma.

Authors:  Rebecca A Kasl; Joshua Hughes; Anthony M Burrows; Fredric B Meyer
Journal:  Childs Nerv Syst       Date:  2015-05-07       Impact factor: 1.475

6.  Pituitary apoplexy precipitating diabetes insipidus after living donor liver transplantation.

Authors:  Takashi Matsusaki; Hiroshi Morimatsu; Junya Matsumi; Hiroaki Matsuda; Tetsufumi Sato; Kenji Sato; Satoshi Mizobuchi; Takahito Yagi; Kiyoshi Morita
Journal:  J Anesth       Date:  2011-01-06       Impact factor: 2.078

7.  Bromocriptine or cabergoline induced pituitary apoplexy: Rare but life-threatening catastrophe.

Authors:  Pratibha Singh; Manish Singh; Goutham Cugati; Ajai Kumar Singh
Journal:  J Hum Reprod Sci       Date:  2011-01

8.  Bromocriptine or cabergoline-induced cerebrospinal fluid rhinorrhea: A life-threatening complication during management of prolactinoma.

Authors:  Pratibha Singh; Manish Singh; Goutham Cugati; Ajai Kumar Singh
Journal:  J Hum Reprod Sci       Date:  2011-05

9.  Giant Prolactinoma Presenting with Neck Pain and Structural Compromise of the Occipital Condyles.

Authors:  Derek Yecies; Abdulrazag Ajlan; John Ratliff; Jennifer Ziskin; Peter Hwang; Hannes Vogel; Laurence Katznelson; Griffith Harsh
Journal:  J Neurol Surg Rep       Date:  2015-10-29

10.  Successful pregnancy in a female with a large prolactinoma after pituitary tumor apoplexy.

Authors:  Butheinah A Al-Sharafi; Omar H Nassar
Journal:  Case Rep Obstet Gynecol       Date:  2013-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.